Clinical Trial Update: Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating pharmacokinetics of vildagliptin in mild, moderate, and severe renal impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Vildagliptin (vildagliptin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Renal Impairment, Diabetes | Phase 1, Phase 2 | Status: COMPLETED